Novo touts blood sugar control and cardiovascular benefits of Wegovy pill with new trial data

Novo Nordisk (NVO) posts new late-stage trial data to highlight blood sugar control and cardiovascular benefits associated with its Wegovy in a pill. Read more here.
Verywell Health on MSN

We Asked a Doctor If You Should Track Your Blood Sugar Even If You Don't Have Diabetes

There is limited research on the clinical benefit of continuous glucose monitors (CGMs) in healthy individuals, but anecdotal ...
STAT

Better ways to test AI models for health care, according to one Harvard researcher

Danielle Bittterman on finding vulnerabilities in LLMs to make them safer, in this edition of the AI Prognosis newsletter.
Healio

Multidisciplinary comprehensive obesity care model boosts weight loss, medication persistence

Participants in a multidisciplinary comprehensive obesity care model had clinically meaningful weight loss and high obesity ...
Labiotech.eu

Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic

Novo Nordisk’s weaker results indicate mounting pressure in the weight-loss drug market that it once dominated. The maker of Ozempic and Wegovy is facing tougher competition, slower demand, and ...